Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

CD7 chimeric antigen receptor modified NK-92MI cell and application thereof

A technology of chimeric antigen receptors and NK cells, applied in genetically modified cells, cells modified by introducing foreign genetic material, receptors/cell surface antigens/cell surface determinants, etc., can solve CAR-T cell killing And other issues

Active Publication Date: 2019-04-19
PERSONGEN BIOMEDICINESUZHOUCO
View PDF15 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, designing CARs against T-cell tumors still faces great challenges, because the same antigens are expressed on normal T-cells and T-cell malignancies, causing CAR-T cells to kill each other

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CD7 chimeric antigen receptor modified NK-92MI cell and application thereof
  • CD7 chimeric antigen receptor modified NK-92MI cell and application thereof
  • CD7 chimeric antigen receptor modified NK-92MI cell and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0225] Example 1 Construction of CD7-CAR / dCD7-CAR vector and CAR-NK-92MI cells

[0226] Two CD7-CARs were constructed using the CD7 Nanobody sequence VHH6 monovalent (SEQ ID NO.: 1) and bivalent sequence (SEQ ID NO.: 2). The monovalent CD7-CAR is composed of signal peptide, anti-CD7 Nanobody sequence (VHH6), human Fc hinge region, CD28 transmembrane domain and CD28 and 4-1BB intracellular signaling domains in series with CD3ζ signaling domain. The bivalent dCD7-CAR contains signal peptide, anti-CD7 Nanobody repeat sequence (VHH6-VHH6), human Fc hinge region, CD28 transmembrane domain, and CD28 and 4-1BB intracellular signal transduction in series with CD3ζ signaling domain Structural domain. The structure diagram of CAR is as figure 1 Shown in A. The CD7-CAR and dCD7-CAR sequences were cloned into the pHULK PiggyBac electrotransformation expression vector and named as the CD7-CAR plasmid and dCD7-CAR plasmid, respectively.

[0227] After electroporation, CD7-CAR-NK-92MI and dCD...

Embodiment 2

[0229] Example 2 Expression of CD7 in NK-92MI and T-ALL cells

[0230] The expression of CD7 in NK-92MI, CD7-CAR-NK-92MI and dCD7-CAR-NK-92MI cells was detected by flow cytometry. The results showed that the positive rate of CD7 in NK-92MI cells was 8.42%, while the positive rate of CD7 in NK-92MI cells transfected with CD7-CAR (dCD7-CAR) was less than 1% ( figure 2 A). It shows that CD7-CAR-NK-92MI or dCD7-CAR-NK-92MI cells can specifically kill CD7-positive NK-92MI cells. This example also detected the expression of CD7 on the surface of leukemia cell lines (Jurkat and CCRF-CEM), lymphoblastic cell lines (Raji) and primary tumor cells from T-ALL. The results showed that the CD7 positive rate in CCRF-CEM and Jurkat cells was almost 100% ( figure 2 B), the CD7 positive rate of T-ALL primary tumor cells is 93% ( figure 2 C, the control group is T-ALL cells that have not been incubated with CD7 antibody), while Raji cells are CD7-negative cells ( figure 2 B).

Embodiment 3

[0231] Example 3 In vitro killing activity of CD7-CAR-NK-92MI and dCD7-CAR-NK-92MI cells on T-ALL cell line

[0232] CD7-positive T-ALL cell lines (CCRF-CEM and Jurkat cells) were used to evaluate the in vitro anti-tumor activity of CD7-CAR-NK92-MI and dCD7-CAR-NK92-MI cells. Raji serves as a negative cell line. After co-cultured with CCRF-CEM cells in vitro for 4 hours or 24 hours (effective target ratio 1:1), the cytotoxicity of CD7-CAR-NK92-MI and dCD7-CAR-NK92-MI cells to target cells was detected by flow cytometry. The results showed that compared with control NK92-MI cells, CD7-CAR-NK-92MI and dCD7-CAR-NK-92MI cells showed significant specific cytotoxicity to CCRF-CEM cells under conditions of different effective target ratios. ( image 3 A). This example also evaluated the cytotoxicity of CD7-CAR-NK-92MI and dCD7-CAR-NK-92MI cells to Jurkat cells under the conditions of the effective target ratio of 1:1 and 5:1. The results showed that after 24 hours of incubation with ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a CD7 chimeric antigen receptor modified NK-92MI cell and an application thereof. Particularly, the invention provides an engineered NK cell that expresses a chimeric antigen receptor CAR, the antigen binding domain of which contains a nanoantibody VHH sequence targeting CD7. The NK cell can effectively kill tumor cells, especially T cell tumors, and has very good treatmenteffect on T cell leukemia (such as T-ALL).

Description

Technical field [0001] The present invention belongs to the field of biomedicine. Specifically, the present invention relates to CD7 chimeric antigen receptor modified NK-92MI cells and applications thereof. Background technique [0002] T-cell malignant tumors represent a type of blood system cancer, with high recurrence and mortality rates in children and adults. There is currently no effective or targeted therapy. T-cell acute lymphoblastic leukemia (T-ALL) is a highly heterogeneous hematological malignancy, accounting for 25% of adult acute lymphoblastic leukemia cases and 15% of pediatric acute lymphoblastic leukemia cases. Currently, T-ALL treatment strategies include intensive chemotherapy, allogeneic hematopoietic stem cell transplantation (allo-HSCT), antiviral therapy and molecular targeted therapy. However, intensive chemotherapy and allo-HSCT usually cannot prevent and treat refractory relapses. For those patients who relapse after initial treatment, the remission r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/10C12N15/85C12N15/62A61K35/17A61P35/00
CPCA61P35/00A61K35/17C12N5/0646C07K14/7051C07K16/28C07K2319/00C12N2510/00C07K14/70578A61K38/00A61P35/02C07K14/70521C07K14/70517C07K14/705A61K39/4631C07K16/2803C07K2317/569C07K2317/22A61K39/4613C07K2317/73A61K2039/505A61K39/464411A61K39/4611A61K2239/48A61K2239/29A61K2039/5156C07K2317/35C07K2317/53C07K2319/02C07K2319/03C07K2319/30C07K2319/33
Inventor 杨林游凤涛
Owner PERSONGEN BIOMEDICINESUZHOUCO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com